New therapeutic agents in gastrointestinal stromal tumours

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumour (GIST) treatment has historically relied on tyrosine kinase inhibitors.
• Understanding the molecular heterogeneity of GIST is crucial for personalized therapy.

Purpose of the Study:

• To review recent advancements in systemic treatments for diverse molecular subtypes of GIST.
• To highlight emerging therapies targeting specific genetic alterations in GIST.

Main Methods:

• Literature review of recent clinical trials and research publications.
• Analysis of novel drug candidates and their molecular targets.

Main Results:

• New direct inhibitors of KIT and PDGFRA, such as avapritinib and ripretinib, show promise in advanced clinical development.
• These agents exhibit increased potency and specificity against various KIT and PDGFRA mutations.
• Next-generation drugs may offer the first effective treatments for PDGFRA D842V mutations.
• Comprehensive molecular testing can identify actionable targets like NTRK fusions in KIT/PDGFRA-wildtype GIST.

Conclusions:

• The GIST treatment landscape is evolving rapidly with the advent of more effective drugs.
• Personalized treatment strategies based on molecular profiling are becoming increasingly important for GIST management.